DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.
1996 Caraglia, M.; Leardi, A.; Ricciardi, B.; DE LAURENTIIS, Michelino; Lentini, M. L.; Graziano, ; Matano, Elide; DE PLACIDO, Sabino; Bianco, ANGELO RAFFAELE; Tagliaferri, P.
Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?
1994 C. L., Loprinzi; P. M., Ravdin; DE LAURENTIIS, Michelino; P., Novotny
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
1993 A. R., Bianco; DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; DE LAURENTIIS, Michelino; L., Del Mastro; R., Lauria; Marinelli, Alfredo; C., Gallo
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
1995 DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; A., Morabito; Pagliarulo, Clorindo; Lauria, Rossella; Marinelli, Alfredo; DE LAURENTIIS, Michelino; E., Varriale; Petrella, Giuseppe
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
2010 Gori, S; Di Maio, M; Pinto, C; Alabiso, O; Baldini, E; Beretta, Gd; Caffo, O; Caroti, C; Crinò, L; DE LAURENTIIS, Michelino; Dinota, A; Di Vito, F; Gebbia, V; Giustini, L; Graiff, C; Guida, M; Lelli, G; Lombardo, M; Muggiano, A; Puglisi, F; Romito, S; Salvagno, L; Tagliaferri, P; Terzoli, E; Venturini, M; AIOM Working Group Interaction with Regional, Sections
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
2003 Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.
2003 DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.
2008 Cancello, G.; Montagna, E.; D'Agostino, D.; Giuliano, Mario; Giordano, A.; Di Lorenzo, G.; Plaitano, M.; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases.
1996 Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A.
2000 Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo
Prognostic factors in human colorectal cancer.
1997 A. R., Bianco; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; G., Tortora; F., Ciardiello
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE.
2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.
1998 DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R.
External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life.
2003 DI LORENZO, G; Autorino, R; Ciardiello, F; Raben, D; Bianco, C; Troiani, T; Pizza, C; DE LAURENTIIS, Michelino; Pensabene, M; D., ARMIENTO M; Bianco, Ar; DE PLACIDO, Sabino
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study.
1997 Fontanini, G.; Lucchi, M.; Vignati, S.; Mussi, A.; Ciardiello, F.; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. | 1.1 Articolo in rivista | 1996 | Caraglia, M.; Leardi, A.; Ricciardi, B.; DE LAURENTIIS, Michelino; Lentini, M. L.; Graziano, ; Matano, Elide; DE PLACIDO, Sabino; Bianco, ANGELO RAFFAELE; Tagliaferri, P. | |
| Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? | 1.1 Articolo in rivista | 1994 | C. L., Loprinzi; P. M., Ravdin; DE LAURENTIIS, Michelino; P., Novotny | |
| Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. | 1.1 Articolo in rivista | 1993 | A. R., Bianco; DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; DE LAURENTIIS, Michelino; L., Del Mastro; R., Lauria; Marinelli, Alfredo; C., Gallo | |
| CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). | 1.1 Articolo in rivista | 1995 | DE PLACIDO, Sabino; F., Perrone; Carlomagno, Chiara; A., Morabito; Pagliarulo, Clorindo; Lauria, Rossella; Marinelli, Alfredo; DE LAURENTIIS, Michelino; E., Varriale; Petrella, Giuseppe | |
| A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino | |
| Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). | 1.1 Articolo in rivista | 2010 | Gori, S; Di Maio, M; Pinto, C; Alabiso, O; Baldini, E; Beretta, Gd; Caffo, O; Caroti, C; Crinò, L; DE LAURENTIIS, Michelino; Dinota, A; Di Vito, F; Gebbia, V; Giustini, L; Graiff, C; Guida, M; Lelli, G; Lombardo, M; Muggiano, A; Puglisi, F; Romito, S; Salvagno, L; Tagliaferri, P; Terzoli, E; Venturini, M; AIOM Working Group Interaction with Regional, Sections | |
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. | 1.1 Articolo in rivista | 2003 | Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara | |
| Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. | 1.1 Articolo in rivista | 2003 | DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino | |
| Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. | 1.1 Articolo in rivista | 2008 | Cancello, G.; Montagna, E.; D'Agostino, D.; Giuliano, Mario; Giordano, A.; Di Lorenzo, G.; Plaitano, M.; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino | |
| C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. | 1.1 Articolo in rivista | 1996 | Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. | 1.1 Articolo in rivista | 2000 | Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo | |
| Prognostic factors in human colorectal cancer. | 1.1 Articolo in rivista | 1997 | A. R., Bianco; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; G., Tortora; F., Ciardiello | |
| IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino | |
| c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. | 1.1 Articolo in rivista | 1998 | DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R. | |
| External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; Ciardiello, F; Raben, D; Bianco, C; Troiani, T; Pizza, C; DE LAURENTIIS, Michelino; Pensabene, M; D., ARMIENTO M; Bianco, Ar; DE PLACIDO, Sabino | |
| SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
| Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. | 1.1 Articolo in rivista | 1997 | Fontanini, G.; Lucchi, M.; Vignati, S.; Mussi, A.; Ciardiello, F.; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino |